ENDP INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Endo
International, PLC Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Endo
International, PLC (“Endo” or the “Company”) (NASDAQ: ENDP) securities between September 28, 2015, and February 28, 2017, inclusive (the “Class Period”) Endo
investors have until January 16, 2018 to file a lead plaintiff motion.
Investors suffering losses on their Endo investments are encouraged to contact the Law Offices of Howard G. Smith to discuss
their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
The Complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and
misleading statements regarding the Company’s alleged collusion with several industry peers to fix drug prices. Specifically,
Defendants made false and/or misleading statements and/or failed to disclose that: (i) Par Pharmaceutical had colluded with several
of its industry peers to fix generic drug prices; (ii) the foregoing conduct constituted a violation of federal antitrust laws;
(iii) the competitive advantages of the Par Pharmaceutical Acquisition, which Endo touted to its shareholders as, inter
alia, “a compelling opportunity to drive future double-digit growth, serve our customers and build shareholder value,” were in
fact derived in part from Par Pharmaceutical’s illegal conduct and thus unsustainable; (iv) for the same reasons, the “impressive
track record of delivering strong operating results” that Endo attributed to former Par Pharmaceutical executive Paul Campanelli in
announcing his promotion to Endo’s CEO consisted in part of illegal conduct; (v) for the foregoing reasons, Endo’s revenues during
the Class Period were in part the result of illegal conduct and likewise unsustainable; and (vi) as a result of the foregoing,
Endo’s public statements were materially false and misleading at all relevant times
If you purchased shares of Endo, have information or would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of
Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847,
toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180108006114/en/